STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #330 by analyst upside · 2026-06-27
IFRX
InflaRx N.V.
Healthcare · Market Cap $283M · P/E 0x
ANALYST PRICE TARGET
+304.2%
implied upside to consensus target
Current Price $1.92
Consensus Target $7.76
Bull Target $13.55
Bear Target $2.91
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
2
Sell
0
52-Week Low $0.74
52-Week High $2.95
YTD Return +76.1%
FUNDAMENTALS
Market Cap $283M
P/E Ratio (TTM) N/A
Forward P/E -4.5x
EPS (TTM) $-0.72
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.74
52-Week High $2.95
Current Price $1.92
Bear Target $2.91
Bull Target $13.55
● Now $1.92 ● Target $7.76
TRADING DATA
Avg Volume 1.8M
YTD Return +76.1%
Analyst Count 7
Consensus Buy
Upside to Target +304.2%
Last Updated 2026-06-27

ANALYST SUMMARY

InflaRx N.V. (IFRX) is currently trading at $1.92 with a Wall Street consensus price target of $7.76, implying potential upside of 304.2% over the next 12 months. 7 analysts currently cover IFRX, with a consensus rating of Buy - 71% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $13.55, while the most cautious has a target of $2.91.

IFRX operates in the Healthcare sector with a market capitalisation of $283M. The stock is up 76.1% year-to-date and is currently trading near the upper end of its 52-week range of $0.74 – $2.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IFRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Raymond James ↑ Upgrade
Outperform → Strong Buy 2026-05-13 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-11 31% win rate (48 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-05-11 40% win rate (10 calls)
Guggenheim reit
Buy → Buy 2026-04-21 62% win rate (8 calls)
Guggenheim — Reiterated
Buy → Buy 2026-03-20 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-12-30 31% win rate (48 calls)
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2025-12-03 29% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2025-11-10 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
30
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →